Houston Methodist Cancer Center, Houston, TX
Jian Guan , Bin S. Teh , Amy Schefler , Eric Bernicker
Background: Metastatic uveal melanoma carries a poor prognosis, especially for patients who are not eligible for Tebentafusp. Unlike cutaneous melanoma, checkpoint inhibitors have limited effect on uveal melanoma. The observation of Abscopal effect has inspired this study of adding radiotherapy to boost the efficacy of immunotherapy. Methods: We performed a retrospective study in Houston Methodist Hospital to evaluate the efficacy of combining immunotherapy with radiotherapy including either SBRT or Y-90 treatment. Clinical outcomes were determined by assessing best overall response according to the Response Evaluation Criteria in Solid Tumors (version 1.1), progression-free survival(PFS) and overall survival. Results: A total of 8 patients were included for this study, among which one patient had previously progressed on immunotherapy. The median follow-up period was 19 months. The best overall response rate (ORR) and disease control rate (DCR) were 25% and 75% in patients received dual-modality combination treatment (including one complete response and one partial response). The PFS and overall survival in dual-modality combination treatment group were 5.4 months (95% CI, 1.1 to 14.9 months) and 18.7 month (95% CI, 11.1 to 23.9 months), respectively. Fifty percent of patients experienced grade 3-4 treatment-related adverse events. Conclusions: The combination of radiotherapy and immunotherapy is active in metastatic uveal melanoma with sustained response in selected patients. A randomized prospective trial may be required to confirm the benefits of dual-modality combination treatment.
Total | N=8 |
---|---|
Sex | |
Female | 4(50) |
Male | 4(50) |
Age, years, median(range) | 57(49-85) |
Eye local therapy | |
Plaque | 7(87.5) |
Enucleation | 1(12.5) |
Gene Expression Profile | |
Class 1A | 1(12.5) |
Class 1B | 1(12.5) |
Class 2 | 6(75) |
Not tested | 0 |
PRAME test | |
Positive | 4(50) |
Negative | 2(25) |
Not tested | 2(25) |
Sites of metastatic disease | |
Liver only | 4(50) |
Approach of radiotherapy | |
SBRT(25-40Gy) | 6(75) |
IMRT(4GyX15) | 1(12.5) |
Y90 | 1(12.5) |
IO agents | |
Nivolumab and/or Ipilimumab | 7(87.5) |
Pembrolizumab | 1(12.5) |
Prior adjuvant therapy | |
Sunitinib | 2(25) |
Types of prior therapy in metastatic setting | |
Immunotherapy | 1(12.5) |
Type of subsequent systemic therapy | |
Targeted therapy | 4(50) |
Chemotherapy | 2(25) |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Sophie Piperno-Neumann
2022 ASCO Annual Meeting
First Author: Sufana Shikdar
2023 ASCO Annual Meeting
First Author: Matthew Lee
2022 ASCO Annual Meeting
First Author: Josep M. Piulats